Apexigen Announces First Patient Dosed in Phase 3 Pivotal Trial for BD0801, an Anti-VEGF Monoclonal Antibody, in Combination Therapy for Ovarian Cancer
- BD0801, discovered using Apexigen’s APXiMAB™ antibody technology platform, is in development by Simcere in China through a licensing agreement -SAN...